S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:OMED - Oncomed Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.89
0.00 (0.00 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$0.89
Now: $0.89
$0.89
50-Day Range
$0.89
MA: $0.89
$0.89
52-Week Range
$0.55
Now: $0.89
$3.35
VolumeN/A
Average Volume768,904 shs
Market Capitalization$34.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.42 million
Book Value$1.25 per share

Profitability

Net Income$-8,100,000.00

Miscellaneous

Employees22
Market Cap$34.43 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive OMED News and Ratings via Email

Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter.


Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions

What is Oncomed Pharmaceuticals' stock symbol?

Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were Oncomed Pharmaceuticals' earnings last quarter?

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative return on equity of 13.14% and a negative net margin of 18.24%. View Oncomed Pharmaceuticals' Earnings History.

When is Oncomed Pharmaceuticals' next earnings date?

Oncomed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Oncomed Pharmaceuticals.

Has Oncomed Pharmaceuticals been receiving favorable news coverage?

News articles about OMED stock have trended very negative on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Oncomed Pharmaceuticals.

Who are some of Oncomed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oncomed Pharmaceuticals own?

Who are Oncomed Pharmaceuticals' key executives?

Oncomed Pharmaceuticals' management team includes the folowing people:
  • Mr. Perry A. Karsen, Exec. Chairman (Age 64)
  • Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Ann Kapoun Ph.D., Sr. VP of Translational Medicine

What is Oncomed Pharmaceuticals' stock price today?

One share of OMED stock can currently be purchased for approximately $0.89.

How big of a company is Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals has a market capitalization of $34.43 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe.View Additional Information About Oncomed Pharmaceuticals.

What is Oncomed Pharmaceuticals' official website?

The official website for Oncomed Pharmaceuticals is http://www.oncomed.com/.

How can I contact Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]


MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  566
MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel